Skip to main content

Articles

Access Market Intelligence Introduces Online Glossary of Common Drug Related Terms and Acronyms as e-Book

A Multistakeholder Consensus on Challenges and Solutions to the Adoption of Biosimilars

“Alexa, Refill My Omeprazole”

David B. Nash, MD, MBA

Original Research

Prospective Bundled Payments in a Changing Environment: The Experience of a Self-Funded, State-Sponsored Plan

Frank H. Lawler, MD, MSPH; Frank R. Wilson, CPA; G. Keith Smith, MD; Lynn V. Mitchell, MD, MPH

Stakeholder Perspective

Oklahoma Benefits Program Setting an Example: A Cost-Effective Bundled Payments Option for State Employees

James T. Kenney, RPh, MBA

Original Research, Practice Management

The Effects of a Sitagliptin Formulary Restriction Program on Diabetes Medication Use

Yuexin Tang, PhD; Xingyue Huang, PhD; Jinan Liu, PhD; R. Ravi Shankar MD; Michael L. Ganz, PhD; Swapnil Rajpathak, MD, DrPH

Stakeholder Perspective

Impact of Step Therapy Restrictions in Diabetes Care

Quang T. Nguyen, DO, FACP, FACE, FTOS

Conference Highlights AMCP

AMCP Nexus 2017 Highlights

Practice Management

Comparing the Medicaid Retrospective Drug Utilization Review Program Cost-Savings Methods Used by State Agencies

Sergio I. Prada, MPA, PhD

Stakeholder Perspective

Is the Federal Drug Utilization Review Requirement Just Red Tape or an Enlightened State of Flexibility?

Michael Kleinrock

ASH 2017 - Chronic Lymphocytic Leukemia

Acalabrutinib with Obinutuzumab in Relapsed/Refractory and Treatment-Naïve Patients with CLL: The Phase 1b/2 ACE-CL-003 Study

ASH 2017 - Chronic Lymphocytic Leukemia

Adverse Events, Resource Use, and Economic Burden in Patients with Mantle-Cell Lymphoma in the United States

ASH 2017 - Chronic Lymphocytic Leukemia

High Complete Response Rates with Pembrolizumab with Rituximab in Patients with Relapsed FL: Results of an Open-Label, Phase 2 Study

Page 76 of 244
Results 751 - 760 of 2434